logo
logo
Search For Features
/
StocksStocks
Intraday BoosterIntraday Booster
Sector BoosterSector Booster
Stock ScreenerStock Screener
Market PulseMarket Pulse
ScreenersScreeners
MoreMore
prime iconGo Prime
My PlansMy Plans
Privacy PolicyPrivacy Policy
ContactContact
Refer & EarnRefer & Earn
ScreenersScreeners
Main
Stock ScreenerStock Screener
Create ScreenerCreate Screener
Explore ScreenersExplore Screeners
Community ScreenersCommunity Screeners
Trading Screeners
CandleSticks ScreenerCandleSticks Screener
Top Gainers & LosersTop Gainers & Losers
Opening Range BreakoutOpening Range Breakout
Stock Screener AIStock Screener AI
Stock Quality ScorecardStock Quality Scorecard
Overvalued StocksOvervalued StocksNew
Undervalued StocksUndervalued StocksNew
Technical Screeners
NR4 StocksNR4 Stocks
NR7 StocksNR7 Stocks
Previous Day High BreakoutPrevious Day High Breakout
Previous Day Low BreakoutPrevious Day Low Breakout
Previous Day Open BreakoutPrevious Day Open Breakout
Bullish Crossover StocksBullish Crossover Stocks
Bearish Crossover StocksBearish Crossover Stocks
High Volume ShockerHigh Volume Shocker
VWAP Breakout StocksVWAP Breakout Stocks
Range High BreakoutRange High Breakout
Range Low BreakoutRange Low Breakout
MoreMore
Markets
Global Market TodayGlobal Market Today
Global IndicesGlobal Indices
Indian IndicesIndian Indices
NIfty TodayNIfty Today
Precious Metals
Gold Price TodayGold Price TodayNew
Silver Price TodaySilver Price TodayNew
Platinum Price TodayPlatinum Price TodayNew
Smart Money
FII DII DataFII DII DataNew
FII BuyingFII Buying
NSE Insider TradingNSE Insider Trading
SLB Stocks DataSLB Stocks Data
Derivatives
FnO MovementsFnO Movements
NSE F&O Lot SizeNSE F&O Lot Size
Ban ListBan List
Analysis & Calendars
Technical DashboardTechnical Dashboard
Sector BoosterSector Booster
Sector AnalysisSector AnalysisNew
Result CalendarResult Calendar
Economic CalendarEconomic Calendar
Thyrocare Technologies Ltd

Thyrocare Technologies

Mid Cap•1,693 Employees•IPO 2016
Current Price
₹400.30
-4.05 (-1%)Updated
NSE :THYROCARE
BSE :539871
Sector :Health Care Providers & Services
Today's Range
398
₹400.30
indicator
405.65
52 Week Range
52W Low₹342.55
52W High₹1610.00
₹400.30
indicator
Downside16.86%
Upside302.20%
chart iconChart

Price Chart

Compare with Peers

Historical Ratios

Track top 12 most important financial ratios

P/E Ratio: Price to Earnings - Most used valuation metric

Loading chart...

Analyzing Investment Quality

Processing 9 key metrics...

Key Metrics

Hover for details

Valuation

Market Cap
₹6,697.52 Cr
Market Cap
Total market value of company
P/E Ratio
48.67
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)
P/B Ratio
11.51
P/B Ratio
Price to Book Value. <3 may indicate undervaluation
EPS
₹8.71
EPS
Earnings Per Share. Higher and growing is positive

Profitability

ROE
12.89%
ROE
Return on Equity. >15% is good, >20% is excellent
ROCE
24.80%
ROCE
Return on Capital Employed. >15% is good
Net Margin
17.37%
Net Margin
Net profit as % of revenue. >10% is good
Operating Margin
-%
Operating Margin
Operating profit margin. >15% is good

Growth

EPS Growth (5Y)
-19.23%
EPS Growth (5Y)
5-year EPS growth. >15% is strong
Revenue Growth (5Y)
9.67%
Revenue Growth (5Y)
5-year revenue growth. >10% is good
Qtr Sales Growth
22.10%
Qtr Sales Growth
Quarter-over-quarter sales growth
Qtr Profit Growth
79.90%
Qtr Profit Growth
Quarter-over-quarter profit growth

Financial Health

Debt/Equity
0.05
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellent
Book Value
₹34.39
Book Value
Net asset value per share
Dividend Yield
1.66%
Dividend Yield
Annual dividend as % of price. >2% is good
Promoter Holding
71.00%
Promoter Holding
Promoter stake. >50% shows confidence
Good
Average
Needs Attention

SWOT Analysis

Strengths

5 points
  • •Robust profitability: OPM 29.90%, ROCE 24.80% indicate efficient operations.
  • •Strong recent growth: Quarterly profit surged 79.90%, sales increased 22.10%.

Weaknesses

5 points
  • •High valuation: P/E ratio of 64.77 suggests potential overvaluation.
  • •Declining FII confidence: FII holding decreased from 12.82% to 4.85%.

Opportunities

3 points
  • •Expanding healthcare sector drives demand for diagnostic services.
  • •Growing focus on preventive healthcare offers service expansion avenues.

Threats

3 points
  • •Intense industry competition from established players creates pricing pressure.
  • •Evolving healthcare regulations could impact operational costs and profitability.

Segment-wise Financial Analysis

Fetching Financials...
Fetching Balance Sheet...
Fetching Cash Flow...

Shareholding Pattern

Loading shareholding data...

Company Insider Trading Activity

Recent Insider Transactions

Insider NameTransaction DateFiling DateTotal SharesChangePriceAction
Priyanka Jagnani Jain
30 Jan 202531 Jan 20251,500
245
₹776.42BUY
Priyanka Jagnani Jain
28 Jan 202531 Jan 20251,255
555
₹765.87BUY
Priyanka Jagnani Jain
27 Jan 202531 Jan 2025700
200
₹761BUY

Corporate Action

Company Announcements

Technical Analysis & Indicators

Standard pivot points - most widely used

Pivot Points (CLASSIC)

LevelPriceDistance% Change
R4₹419.93+₹19.63+4.90%
R3₹412.28+₹11.98+2.99%
R2₹408.97+₹8.67+2.17%
R1₹404.63+₹4.33+1.08%
PIVOT₹401.321.020.25%
CURRENT₹400.30--
S1₹381.68-₹18.62-4.65%
S2₹389.33-₹10.97-2.74%
S3₹393.67-₹6.63-1.66%
S4₹396.98-₹3.32-0.83%
CPR Levels
Support
Resistance
S4
S3
S2
S1
| CPR |
BC: N/AP: N/ATC: N/A
R1
R2
R3
R4
indicator
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment

is trading CPR, indicating

● CPR Width

CPR is

● Opening Range

Day's range: ~

● Price Position

Trading Inside opening range

Delivery Volume Analysis & Trading Activity

Latest Volume
1.41L
(30 Apr 2026)
-27.0% vs avg
Delivery %
43.9%
(30 Apr 2026)
-8.9% vs avg
Avg Volume (20D)
1.93L
(01 Apr - 30 Apr)
20-day average
Avg Delivery %
52.8%
(01 Apr - 30 Apr)
Trend ↑
Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.

Peer Comparison & Industry Benchmarking

Quick Compare

Largest by Market Cap
Dr Lal Pathlabs Ltd
24,046.66 ₹ Cr
Best Profit Growth
Dr Lal Pathlabs Ltd
24.40 %
Highest Dividend Yield
Dr Lal Pathlabs Ltd
0.85 %

Peer Comparison

Company Name
KRSNAA
Krsnaa Diagnostics Ltd
LALPATHLAB
Dr Lal Pathlabs Ltd
METROPOLIS
Metropolis Healthcare Ltd
SURAKSHA
Suraksha Diagnostic Ltd
VIJAYA
Vijaya Diagnostic Centre Ltd

About

THYROCARE

Thyrocare Technologies Ltd

Thyrocare Technologies Limited is a prominent Indian healthcare company specializing in diagnostic testing services. Its primary business revolves around providing a wide range of medical tests to patients, hospitals, and other laboratories across the country. The company’s focus is on early detection and proactive management of various health conditions, contributing to preventative healthcare.

Thyrocare's services encompass a broad spectrum of diagnostic tests, targeting numerous health areas. These include thyroid disorders (the company's namesake), growth and metabolic issues, autoimmune diseases, diabetes, anemia, cardiovascular health concerns, infertility, and a variety of infectious diseases. This comprehensive approach allows for a holistic assessment of patient health, aiding in early diagnosis and subsequent treatment.

The company operates under a three-segment structure: Diagnostic Testing Services, Imaging Services, and Others. The Diagnostic Testing Services segment forms the core of Thyrocare's business, encompassing the vast majority of its testing portfolio. The Imaging Services segment likely includes diagnostic imaging procedures, although the provided text does not offer specifics. The "Others" segment appears to encompass ancillary products and services, such as the sale of glucometers and glucostrips under the Sugarscan brand, as well as consumables and radiopharmaceutical products.

A significant aspect of Thyrocare's strategy is its Aarogyam brand. This brand offers a suite of wellness and preventive healthcare tests, catering to individuals focused on proactive health maintenance. These profiles of tests are designed to identify potential health risks early on, allowing for timely intervention and improved health outcomes. By offering a range of tests, from specialized diagnostic tests to comprehensive wellness packages, Thyrocare aims to cater to a wide patient base and various healthcare needs.

In summary, Thyrocare Technologies Limited is a vertically integrated diagnostics company focused on providing a comprehensive suite of testing services aimed at early disease detection and preventive healthcare. Its diverse offerings, including specialized tests, wellness packages, and ancillary products, position it as a major player in the Indian healthcare market. The company's success hinges on its ability to deliver accurate, timely, and cost-effective diagnostic services across a broad range of health conditions.

COMPANY FACTS - THYROCARE

Registered Address

D-37/1, Midc, Turbhe, Opp., Sandoz

Navi Mumbai

MAHARASHTRA

IN

Tel: 912241252525

Website:https://www.thyrocare.com/

Investor Relations:http://investor.thyrocare.com/
Company Details

Group: Health Care Equipment & Services

Sector: Health Care

Industry: Health Care Providers & Services

Exchange: NATIONAL STOCK EXCHANGE OF INDIA

Employees: 1,693

IPO Date: 09/05/2016

MANAGEMENT - THYROCARE

Mr. Rahul Guha

Executive Chairman of the Board, Chief Executive Officer, Managing Director

Mr. Vikram Gupta

Chief Financial Officer

Mr. Brijesh Kumar

Compliance Officer, Company Secretary

Mr. Hardik Dedhia

Non-Executive Non-Independent Director

Mr. Alok Jagnani

Non-Executive Non-Independent Director

Dr. Dhaval Shah

Non-Executive Non-Independent Director

Mr. Dharmil Sheth

Non-Executive Non-Independent Director

Dr. Prapti Gilada

Non-Executive Independent Director

Dr. Indumati Gopinathan

Non-Executive Independent Director

Mr. Nishant Shah

Non-Executive Independent Director

Mr. Anandh Sundar

Non-Executive Independent Director

Dr. Harshil Vora

Non-Executive Independent Director

Investor Questions Answered

Thyrocare Technologies Ltd (THYROCARE) Stock FAQs

Get answers to the most common questions about Thyrocare Technologies Ltd stock price, fundamentals, financial metrics, and investment analysis

The current share price of Thyrocare Technologies Ltd (THYROCARE) is ₹400.3. Today, the stock has declined by ₹4.05 (1.00%), trading in a range of ₹398 to ₹405.65. The stock opened at ₹404 with a trading volume of 1,40,847 shares.
Thyrocare Technologies Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹6,697.52 crores, P/E ratio of 48.67, ROE of 12.89%, and ROCE of 24.80%. The dividend yield stands at 1.66%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Thyrocare Technologies Ltd (THYROCARE) is ₹1,610, while the 52-week low is ₹342.55. Currently trading at ₹400.3, the stock is 4.6% away from its 52-week low and 75.1% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Thyrocare Technologies Ltd stock at ₹400.3 depends on multiple factors. The stock is currently trading with a P/E ratio of 48.67 and P/B ratio of N/A. Today's performance shows a loss of 1.00%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Thyrocare Technologies Ltd offers a dividend yield of 1.66%, which means for every ₹100 invested at the current price of ₹400.3, you can expect to receive approximately ₹1.66 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Thyrocare Technologies Ltd's key financial metrics include: P/E Ratio: 48.67, P/B Ratio: N/A, ROE: 12.89%, ROCE: 24.80%, Dividend Yield: 1.66%, EPS: ₹8.71, Book Value: ₹34.39, Debt-to-Equity: 0.05, and Current Ratio: N/A. The company's market cap stands at ₹6,697.52 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Thyrocare Technologies Ltd stock opened at ₹404 and is currently trading at ₹400.3, showing a decline of ₹4.05 (1.00%). The intraday high is ₹405.65 and low is ₹398. The trading volume stands at 1,40,847 shares, indicating moderate market participation today.
Thyrocare Technologies Ltd has a Price-to-Earnings (P/E) ratio of 48.67, which means investors are willing to pay ₹48.67 for every ₹1 of earnings. With an EPS of ₹8.71, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
Thyrocare Technologies Ltd has a market capitalization of ₹6,697.52 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹400.3) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Thyrocare Technologies Ltd has a book value of ₹34.39 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹400.3, which is 1064.0% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Thyrocare Technologies Ltd has a Return on Equity (ROE) of 12.89% and Return on Capital Employed (ROCE) of 24.80%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These are moderate returns, suggesting decent operational efficiency. Higher percentages generally indicate better financial performance.
Thyrocare Technologies Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Thyrocare Technologies Ltd has a debt-to-equity ratio of 0.05, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Thyrocare Technologies Ltd has an Earnings Per Share (EPS) of ₹8.71, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹400.3 and P/E ratio of 48.67, investors are paying 48.67 times the annual earnings per share. The company may need to improve its earnings performance. Track EPS growth over quarters to assess earnings momentum.
Thyrocare Technologies Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Thyrocare Technologies Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Thyrocare Technologies Ltd stock, consider: 1) Fundamental Analysis - Review P/E (48.67), ROE (12.89%), debt-to-equity (0.05), and growth rates. 2) Technical Analysis - Check 52-week range (₹342.55 - ₹1610.00), moving averages, and chart patterns. 3) Valuation - Compare current price (₹400.30) with book value (₹34.39) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Thyrocare Technologies Ltd share is ₹10.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹400.3 is 3903x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Thyrocare Technologies Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹342.55 - ₹1610.00). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.05 indicates leverage. 4) Liquidity Risk - Based on trading volume of 1,40,847 shares. 5) Valuation Risk - P/E of 48.67 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Thyrocare Technologies Ltd operates in the industry with key metrics: P/E ratio of 48.67, ROE of 12.89%, market cap of ₹6,697.52 crores, and dividend yield of 1.66%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.05), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Thyrocare Technologies Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹400.3, with a 52-week range of ₹342.55 to ₹1610.00. Based on fundamentals like P/E (48.67), ROE (12.89%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Thyrocare Technologies Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹400.30. 2) Fundamental Deterioration - Declining ROE (currently 12.89%), increasing debt (D/E: 0.05), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Thyrocare Technologies Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 1.66%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.